By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Aclaris Therapeutics 

101 Lindenwood Drive
Suite 400
Malvern  Pennsylvania  19355  U.S.A.
Phone: 484-324-7933 Fax: 484-324-7949


SEARCH JOBS


Industry
Pharmaceutical






Company News
Aclaris (ACRS) Reports First Quarter 2017 Financial Results 5/10/2017 12:10:31 PM
Aclaris (ACRS) Announce First Quarter 2017 Financial Results On May 9, 2017 5/10/2017 11:23:57 AM
FDA Accepts Aclaris (ACRS)’ New Drug Application For Topical Treatment Of Seborrheic Keratosis, A Common Skin Condition 5/10/2017 11:15:02 AM
Aclaris (ACRS) Completes Phase I Clinical Trial Of ATI-50001 For The Treatment Of Alopecia Universalis And Alopecia Totalis 5/5/2017 10:53:11 AM
Aclaris (ACRS) To Announce First Quarter 2017 Financial Results On May 9, 2017 5/2/2017 11:13:05 AM
Aclaris (ACRS) Announces Notice Of Allowance For A U.S. Patent Application Covering Lead Candidate A-101 Topical Solution 4/26/2017 10:43:02 AM
Aclaris (ACRS) Announces Notice Of Allowance For Two U.S. Patent Applications Covering Baricitnib And Decernotinib, Respectively, For Hair Loss Disorders 4/4/2017 12:03:46 PM
Aclaris (ACRS) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/15/2017 8:38:46 AM
Aclaris (ACRS) Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis – A Common Skin Condition 2/27/2017 7:58:18 AM
Aclaris (ACRS) To Announce Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017 2/23/2017 11:13:35 AM
12345
//-->